CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs